Announcing MAP’s conference 2020
Patient Access 2020: Innovation for UK market access
Tuesday 22nd September 2020 – Royal College of Physicians, London
A must-attend event for any organisation seeking to bring their medicines, devices and diagnostics to UK patients.
Our conference has been designed around three core market access areas. Each with a specific mission to bring you the latest insights and information for accelerating patient access.
Developments in strategy and HTA
The importance of patient engagement throughout the HTA process
Using patient registries in HTAs
Appraisal process of medical devices compared with drugs
Health economic modelling of digital apps
Access to Orphan Medicines: Developing policies for the future
Innovation tools
Approaches to utilising Real World Evidence (RWE)
Using analytics and big data to gain competitive advantage in Market Access
Collaborative working and horizon scanning
Harnessing digital systems and technology to find new levels of patient value
Pricing and policy
VPAS – what you need to know
Updates on The Commercial Framework
Advanced Therapy Medicinal Products – Responding to new high cost/high value drugs
The NHS Long Term Plan and what this actually means for pharma companies
Who should attend?
This conference should be attended by representatives from UK, European and global pharmaceutical, biotech, life science and MedTech industries, as well as patient organisations and patient groups.
The job functions that will benefit most include:
- Heads of Market Access
- Country Managers
- Health Economists
- Commercial Directors
- Marketing Directors
- Managing Directors
- Chief Executives
- Medical Directors
- Policy Officers/Executives
- Policy Advisors
Agenda
Session One
08:30 – Morning coffee & registration
09:00 – Welcome to Patient Access 2020. Introductions and scene setting
Christian Hill, CEO MAP BioPharma
Developments in strategy and HTA
09:15 – The importance of patient engagement throughout the HTA process
Lindsay Weaver, CEO, Metabolic Support UK
09:45 – Using patient registries in HTAs
David Gillen, Vice President international Medical Affairs, Vertex
10:15 – Appraisal process of medical devices compared with drugs
Melinda Goodall, Associate Director, NICE
Break
10:45 – Refreshments & Networking; Guided tours of MAP Online resources and free consultation clinics; Meet our exhibitors: NIHR Innovation Observatory (NIHRIO); O4 Research; EUCOPE
Session Two
11:15 – Access to Orphan Medicines: Developing policies for the future
Sarah Walker, Senior Consultant Policy and Public Affairs, MAP BioPharma
11:45 – Panel Discussion: Led by MAP’s Policy and Public Affairs team, this interactive session will bring together experts to consider challenges with and solutions for the appraisal of medicines for rare diseases.
Panellists will reflect on the potential for the NICE methods review, proposed Innovative Medicines Fund and other policy levers to improve access to orphan medicines arrangements. Our panel includes:
- Kate Learoyd, Campaign Manager, NSPKU – National Society for Phenylketonuria
- Sheela Upadhyaya, Associate Director Highly Specialised Technologies Program, NICE
- Lindsay Weaver, CEO, Metabolic Support UK
- Member of Parliament – tbc
Break
12:30 – Lunch & Networking; Guided tours of MAP Online resources and free consultation clinics; Meet our exhibitors: NIHR Innovation Observatory (NIHRIO); O4 Research; EUCOPE
Session Three
Innovation tools
13:30 – Approaches to utilising Real World Evidence (RWE)
Andi Orlowski, Head of Business Intelligence, Imperial College Healthcare Partners
14:00 – Collaborative working and Horizon Scanning – The NHS Long Term Plan and what this actually means for pharma companies
Melinda Goodall, Associate Director, NICE
14:30 – Harnessing digital systems and technology to find new levels of patient value
Darren Spevick, Managing Partner, Eventum Partners and Chair of the EMIG Digital Health Special Interest Group.
Break
15:00 – Refreshments & Networking; Guided tours of MAP Online resources and free consultation clinics; Meet our exhibitors: NIHR Innovation Observatory (NIHRIO); O4 Research; EUCOPE
Session Four
Pricing and policy
15:30 – VPAS – what you need to know
David Watson, Director Pricing And Reimbursement, Association of the British Pharmaceutical Industry (ABPI)
16:00 – Commercial and Managed Access in England
Carla Deakin, Programme Director, Commercial & Managed Access, NICE
16:30 – Advanced Therapy Medicinal Products – Responding to new high cost/high value drugs
Outputs from ‘meet the expert’ sessions across Europe in 2020
Christian Hill, Chief Executive Officer, MAP
17:00 – Conference Close – Networking Drinks Reception
Speakers
Confirmed Speakers
- Lindsay Weaver, CEO, Metabolic Support UK – on the importance of patient engagement throughout the HTA process
- David Gillen, Vice President international Medical Affairs, Vertex – on using patient registries in HTAs
- Sheela Uppadhyaya, Associate Director Technology Appraisals and Highly Specialised Technologies, NICE – on Orphan medicines, policy and patient engagement
- Andi Orlowski, Head of Business Intelligence, Imperial College Healthcare Partners – on approaches to utilising Real World Evidence (RWE)
- David Watson, Director Pricing And Reimbursement, Association of the British Pharmaceutical Industry (ABPI) – on the Voluntary Scheme; what you need to know
- Darren Spevick, Managing Partner, Eventum Partners and Chair of the EMIG Digital Health Special Interest Group – on Harnessing digital systems and technology to find new levels of patient value
- Carla Deakin, Programme Director, Commercial & Managed Access, NICE
- Sarah Walker, Senior Consultant Policy and Public Affairs, MAP BioPharma
- Melinda Goodall, Associate Director, NICE
- Kate Learoyd, Campaign Manager, NSPKU – National Society for Phenylketonuria
- Christian Hill, CEO MAP BioPharma
Exhibitors
NIHR Innovation Observatory (NIHRIO)
We are an independent horizon scanning centre based at Newcastle University in the UK. We use advanced horizon scanning techniques to detect new health innovations and track them; from patent-to-patient.
NICE provide UK national guidance for the NHS through their NICE technology appraisal (TA) and highly specialised technology (HST) process. NIHRIO is industry’s gateway to NICE, notifying NICE about new or repurposed drugs 3 years before UK license. This early notification allows NICE to provide new technology guidance as close to the license date as possible, ensuring efficient UK market access.
Website: www.io.nihr.ac.uk
Twitter: @NIHRIO
LinkedIn: https://www.linkedin.com/company/nihr-innovation-observatory/ (#nihrio)
O4 Research
We are a UK and Ireland based, Clinical Research and Site Management Organisation, providing novel, intelligent Clinical Research Solutions proven to deliver studies like yours, on time and within budget. We focus on concept development, branding, patient recruitment and full-service delivery of late phase clinical trials and non-interventional/real-world evidence studies.
Offering peerless flexibility, we also integrate seamlessly with your teams when delivering functional services for global studies or providing bespoke, on and off-site support.
Website: www.o4research.com
LinkedIn: https://www.linkedin.com/company/o4-research-ltd/
EUCOPE – the European Confederation of Pharmaceutical Entrepreneurs
EUCOPE is Europe’s trade body for small to medium-sized innovative companies working in the field of pharmaceuticals and medical technologies.
Based in Brussels, EUCOPE gives voice to more than 900 research-oriented innovative companies and associations active in research, development of pharmaceuticals, biotechnologies and medical devices. Many of our members are developing therapeutic solutions for persons living with a rare disease, who had little to no treatment available just a few years ago.
Website: www.eucope.org
Twitter: @EUCOPE
LinkedIn: https://www.linkedin.com/in/eucope/
